{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:54Z","timestamp":1790115834905,"version":"4.0.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Patients with inflammatory arthritis (IA), including RA and PsA, have an elevated cardiovascular disease (CVD) risk. It is unclear whether this persists in the modern treat-to-target era, particularly in early disease. This study evaluates CVD risk and mortality in a contemporary early RA and PsA cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults (\u226518\u2009years) with newly diagnosed RA or PsA registered in the National Early Inflammatory Arthritis Audit (NEIAA) from 2018 to 2023 were included. Incidence rates of CVD events, major adverse cardiovascular events (MACE) and all-cause and CVD mortality were calculated. Standardized incidence and mortality ratios compared outcomes with the general population. Competing risk regression assessed factors associated with CVD outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1012\/17\u2009669 RA and 104\/3271 PsA participants had CVD hospitalizations. The incidence of MACE hospitalizations was 2.4\/100 person-years (95% CI 2.2, 2.7) in RA and 0.6\/100 person-years (95% CI 0.4, 1.0) in PsA. The risk of CVD hospitalizations was \u224825% higher in IA participants. Compared with the general population, all-cause mortality was 1.1 times higher in RA. CVD incidence and mortality were consistently higher in males. Hypertension, diabetes and smoking were associated with an increased CVD risk. Early corticosteroid use did not predict CVD, while better early RA treatment response was linked to lower CVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A greater incidence of CVD and MACE exists in early IA, although less than previously reported. Traditional CVD risk factors are the dominant explanation for the risk increase, with disease control being a smaller but significant contributor to risk. Routine cardiovascular risk assessment in early IA remains justified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag016","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:42:09Z","timestamp":1768999329000},"source":"Crossref","is-referenced-by-count":2,"title":["Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK"],"prefix":"10.1093","volume":"10","author":[{"given":"Zijing","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Internal Medicine, University of Messina , Messina,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Coalwood","sequence":"additional","affiliation":[{"name":"National Early Inflammatory Autoimmune Diseases Audit, British Society for Rheumatology , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0201","authenticated-orcid":false,"given":"Elizabeth","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya","family":"Buch","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"2026021218161352900_rkag016-B1","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026021218161352900_rkag016-B2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","article-title":"Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis","volume":"16","author":"Semb","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026021218161352900_rkag016-B3","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","volume":"61","author":"Kerola","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026021218161352900_rkag016-B4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026021218161352900_rkag016-B5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/ard.2005.050377","article-title":"Patterns of cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B6","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.11078","article-title":"Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects","volume":"48","author":"del Rinc\u00f3n","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026021218161352900_rkag016-B7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026021218161352900_rkag016-B8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/1756-185X.14147","article-title":"Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis","volume":"24","author":"Loganathan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2026021218161352900_rkag016-B10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2026021218161352900_rkag016-B11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","article-title":"Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms","volume":"75","author":"Arts","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3899\/jrheum.200842","article-title":"Improved incidence of cardiovascular disease in patients with incident rheumatoid arthritis in the 2000s: a population-based cohort study","volume":"48","author":"Myasoedova","year":"2021","journal-title":"J Rheum"},{"key":"2026021218161352900_rkag016-B17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/rheumatology\/kead325","article-title":"Temporal trends in mortality in patients with rheumatoid arthritis: a Danish population-based matched cohort study","volume":"63","author":"Soussi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026021218161352900_rkag016-B18","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1093\/rheumatology\/keae080","article-title":"Risk of cardiovascular disease decreases over time in psoriatic arthritis but not in spondylarthritis: meta-analysis of longitudinal studies","volume":"63","author":"Gouze","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026021218161352900_rkag016-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026021218161352900_rkag016-B21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026021218161352900_rkag016-B22","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","article-title":"Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019","volume":"397","author":"Reitsma","year":"2021","journal-title":"Lancet"},{"key":"2026021218161352900_rkag016-B23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"2026021218161352900_rkag016-B24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026021218161352900_rkag016-B25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2026021218161352900_rkag016-B26","doi-asserted-by":"crossref","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"Herrett","year":"2013","journal-title":"BMJ"},{"key":"2026021218161352900_rkag016-B27","author":"Ministry of Housing, Communities and Local Government","year":"2019"},{"key":"2026021218161352900_rkag016-B28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2026021218161352900_rkag016-B29","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026021218161352900_rkag016-B30","author":"Office of National Statistics"},{"key":"2026021218161352900_rkag016-B31","author":"Office of National Statistics","year":"2022"},{"key":"2026021218161352900_rkag016-B32","author":"Institute for Health Metrics and Evaluation","year":"2020"},{"key":"2026021218161352900_rkag016-B33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026021218161352900_rkag016-B34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2018.03.005","article-title":"Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis","volume":"48","author":"Cooksey","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2026021218161352900_rkag016-B35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B36","doi-asserted-by":"crossref","first-page":"152416","DOI":"10.1016\/j.semarthrit.2024.152416","article-title":"Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: a population-based cohort study","volume":"65","author":"Meng","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026021218161352900_rkag016-B37","doi-asserted-by":"crossref","first-page":"e003485","DOI":"10.1136\/rmdopen-2023-003485","article-title":"Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated","volume":"9","author":"Raadsen","year":"2023","journal-title":"RMD Open"},{"key":"2026021218161352900_rkag016-B38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/ard-2023-224965","article-title":"Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study","volume":"83","author":"Exarchou","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B39","doi-asserted-by":"crossref","first-page":"e078523","DOI":"10.1136\/bmj-2023-078523","article-title":"Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study","volume":"385","author":"Conrad","year":"2024","journal-title":"BMJ"},{"key":"2026021218161352900_rkag016-B40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"2026021218161352900_rkag016-B42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","article-title":"Low disease activity (DAS28\u22643.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study","volume":"76","author":"Arts","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B44","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026021218161352900_rkag016-B45","doi-asserted-by":"crossref","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"10","author":"Baghdadi","year":"2015","journal-title":"PLoS One"},{"key":"2026021218161352900_rkag016-B46","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/annrheumdis-2013-203688","article-title":"Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"72","author":"Corrales","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag016\/66569823\/rkag016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/1\/rkag016\/66569823\/rkag016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/1\/rkag016\/66569823\/rkag016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:16:24Z","timestamp":1770938184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag016\/8440805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag016","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag016"}}